Back to News
Market Impact: 0.2
InflaRx Targets Kidney Protection, Steroid Reduction in AAV With Izicopan Trials
Source: marketbeat.com
Healthcare & BiotechCompany FundamentalsCorporate Guidance & Outlook
InflaRx outlined plans to advance oral C5a receptor antagonist izicopan for ANCA-associated vasculitis (AAV), initially focusing on patients with kidney involvement. A parallel study is intended to evaluate corticosteroid reduction; the article reports no trial results or timelines.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
IFRX0.35
More News
- Binance co-CEO Richard Teng says hackers used fake job interviews, AI tool to steal $6.3 billion in crypto 108511116
- AMD stock jumps 7% on earnings as data center revenue nearly doubles
- Marvell Technology could plunge on latest multibillion-dollar acquisition
- Disney Plans Thousands of Layoffs Companywide
- AMD rides data center riches to ‘largest and most profitable’ quarter in history
- AMD’s OpenAI, Meta chip deals trigger $1 billion quarterly charge